Novartis ’ Rydapt receives approval for two cancer treatments in the EU

The European Commission (EC) has approved Novartis ’ Rydapt (midostaurin) for two indications in rare, hard-to-treat cancers.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news